SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense trading activity as market participants speculate on a potential acquisition by major tech players like Amazon, following reports of ongoing buyout talks that have triggered a massive surge in volume. The community is actively debating the implications of this possible deal, contrasting the potential buyout premium against current market valuations while weighing the company's critical role in satellite connectivity and its long-standing partnership with Apple.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is in the spotlight as investors anticipate the upcoming Artemis II mission, which marks the first crewed deep-space flight in over 50 years. The community is actively debating the stock's long-term potential within the lunar economy while closely monitoring technical price levels and market-wide volatility driven by geopolitical tensions.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently drawing intense investor focus as the market digests the newly confirmed April launch date for its BlueBird 7 satellite, a critical milestone for its direct-to-cell broadband network. While technical delays and macroeconomic pressures have fueled volatility, the community remains deeply divided, with bullish investors aggressively accumulating shares ahead of the SpaceX IPO-driven sector repricing, while bears challenge the company's timeline and execution capacity.

nCino, Inc. engages in the provision of cloud-based software applications for financial institutions in the United States and internationally. Its nCino Bank Operating System, a tenant cloud platform, digitizes, automates, and streamlines complex processes and workflow, and utilizes data analytics and artificial intelligence and machine learning (AI/ML) to enable financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposit and other accounts, and manage regulatory compliance. The firm's nCino IQ is an application suite that utilizes data analytics and AI/ML to provide its customers with automation and insights into their operations, such as tools for analyzing, measuring, and managing credit risk, as well as to enhance their ability to comply with regulatory requirements. The company was founded by Pierre Naudé in 2011 and is headquartered in Wilmington, NC.

Ncino Inc.

nCino is currently in focus following a significant expansion of its stock repurchase program, which has fueled positive community sentiment regarding the company's long-term capital allocation strategy. Investors and analysts are actively debating the stock's valuation after strong earnings performance and management's focus on accelerating growth in its cloud banking and AI-driven product offerings.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors react to the company moving up its earnings report to April 1st, fueling intense speculation about potential surprises or major catalysts. The community remains deeply divided, with bulls highlighting beverage expansion deals and upcoming federal CBD Medicare pilot programs, while vocal critics continue to focus on long-standing frustrations regarding share dilution, leadership, and sector-wide volatility.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is gaining attention as investors digest new contract awards and the company's expanding role in national security and NASA lunar missions. The community is actively debating the impact of ongoing insider selling by private equity firms against the stock's long-term potential in the growing space and defense sectors.

Launchr is a programmable creator fee engine designed to adapt to every stage of a token’s lifecycle.  Instead of hard coded splits or one time choices, Launchr lets creators dynamically route fees in real time based on market conditions, liquidity depth, and strategy.

Launchr

LAUNCHR is generating significant buzz following its recent debut as investors debate the sustainability of the project amidst a broader landscape of speculative, short-term crypto assets.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is currently at the center of a tug-of-war between retail traders anticipating a turnaroundfueled by speculation of increased institutional involvement, potential short squeeze setups, and seasonal travel tailwindsand skeptics highlighting significant debt and earnings volatility. The community remains heavily focused on monitoring call flow and technical indicators, with intense debate over whether current price levels offer a deep-value opportunity or if the stock remains trapped by structural headwinds.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing heightened volatility as retail traders speculate on a potential short squeeze, frequently comparing its low float and share structure to past parabolic meme stock runs. While some community members anticipate a massive rally based on historical spikes, others warn of significant downside risk, characterizing the activity as a high-stakes pump and dump involving extreme borrowing fees.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is seeing significant volatility following the announcement that its Phase 2 clinical trial for ALTO-101 failed to meet primary statistical significance. While the stock has faced sharp downward pressure, the community remains divided, with some investors focusing on the company's shift in strategic priorities toward their lead asset, ALTO-207, and others expressing skepticism about the remaining pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The average 12-month price target on the stock is $18, representing a potential upside of as much as 495% from the stock’s current $3.02 trading levels.</li><li>The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026.</li><li>Truist believes that pemvidutide "could be successful in treating MASH as well as liver-related diseases AUD."</li></ul>Shares of Altimmune (ALT) traded 5% lower on Friday despite Wall Street viewing a potential upside of as much as 495% on the stock.According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.The average 12-month price target on the stock is $18, compared to the stock’s current $3.02 trading levels.<h2 class="st-heading-2">Wall Street Take</h2>Earlier this month, Truist initiated coverage of Altimmune with a ‘Buy’ rating and $12 price target. The firm believes that the company's lead candidate pemvidutide "could be successful in treating MASH."Truist is modelling peak 20,000 patients on pemvidutide, which would result in worldwide "peak adjusted/unadjusted revenue of ~$600million/$1.0billion," it said.<h2 class="st-heading-2">Altimmune Pipeline</h2>Altimmune is a clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). The company’s pemvidutide is in development for the treatment of alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in addition to MASH.The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026. The trial is expected to evaluate multiple pemvidutide doses over a 52-week treatment period.The company is looking forward to announcing topline data from a mid–stage trial of pemvidutide in Alcohol Use Disorder in the third quarter of 2026, and is also enrolling patients into a mid-stage trial of the drug in Alcohol-associated Liver Disease.<h2 class="st-heading-2">Retail Sentiment</h2>On Stocktwits, retail sentiment around ALT stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user expressed disappointment about the stock’s downward trajectory.<stembedurl>https://www.stocktwits.com/Moemazon/message/648788986</stembedurl><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> has dropped 45% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-dives-despite-gene-therapy-approval-wall-street-dismisses-sell-off/cZ3HfqIRImh">RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.

Equity

According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.


ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.

Altimmune Stock: Neutral Outlook With Big 2026 Catalysts

Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.

ALT Pemvidutide Explained: What Makes It Different in MASH

Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning Anti-Aging Protein Research Takes a Step Forward with Cell Cloning PR Newswire VANCOUVER, BC, March 24, 2026 Issued on behalf of Ava...

Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial

Truist Financial initiated coverage on shares of Altimmune in a research note on Wednesday. They issued a "buy" rating and a $12.00 price target on the stock...

What is HC Wainwright's Estimate for Altimmune Q1 Earnings?

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Equities researchers at HC Wainwright raised their Q1 2026 earnings estimates for Altimmune in a report released on Monday, March 16th. HC Wainwright...

HC Wainwright Forecasts Altimmune's Q4 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for Altimmune in a report issued on Monday, March 16th. HC Wainwright...

Altimmune (NASDAQ:ALT) Price Target Raised to $25.00 at HC Wainwright

HC Wainwright raised their target price on Altimmune from $12.00 to $25.00 and gave the company a "buy" rating in a report on Monday...

Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat

Altimmune (NASDAQ:ALT) executives highlighted clinical progress across multiple pemvidutide programs and discussed the company's financing priorities during a Barclays fireside chat, with management...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Stocktwits

Stocktwits Polls

Investors are closely debating the strategic implications and motivation behind recent significant open market share purchases by the CEO and CFO.

Shareholders are expressing deep frustration and anxiety regarding potential share dilution and management's requests for increased authorized share counts.

Traders continue to monitor for potential buyout or partnership news, often comparing current leadership moves to industry standard exit patterns.

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALT News

ALTAltimmune Inc